.svg)
.png)
Cell and gene therapy (CGT) is transforming modern medicine. These therapies offer the potential to treat, and in some cases fundamentally alter the course of, diseases that previously had limited options.
But while the science continues to advance, the operational realities behind these trials present a unique challenge.
In traditional clinical trials, supply risk often means running low on the investigational product. In cell and gene therapy, supply risk can mean something far more significant: the loss of a patient-specific dose that cannot be replaced.
For sponsors and study teams, managing that risk requires a different approach to trial operations—one built around coordination, visibility, and precision at every step of the patient journey.
Unlike conventional therapies, autologous cell and gene therapies are not produced in bulk and stored in inventory.
Each treatment is manufactured from a specific patient's own cells. Those cells are collected, transported to a manufacturing facility, processed, tested, and then returned to the clinical site for administration.
The result is a highly individualized supply chain where every patient effectively has their own manufacturing and logistics workflow.
There is no pooled inventory. No backup stock. No ability to simply ship another dose if something goes wrong.
Success depends on a carefully orchestrated sequence of events:
Each milestone must happen in the correct order and within tightly controlled timelines. A delay at any point can have cascading effects throughout the process.
Cell and gene therapy supply chains involve multiple stakeholders working across different organizations, systems, and processes.
Clinical sites need visibility into patient readiness and scheduling requirements. Manufacturing facilities must manage finite production capacity. Logistics partners are responsible for maintaining the chain of custody and temperature-controlled transportation. Sponsors need oversight across the entire workflow.
The challenge is that these groups often operate within separate systems that don't naturally communicate with one another.
As a result, teams can find themselves relying on:
In an environment where timing is critical, fragmented processes introduce risk.
A manufacturing slot may be reserved before a patient is fully ready.
A shipment may arrive at a site that cannot accommodate the scheduled infusion.
Critical information may be delayed or missed entirely.
In traditional supply chains, some mistakes can be corrected. In cell and gene therapy, many cannot.
A missed manufacturing window, a chain-of-identity issue, or a logistical failure can jeopardize treatment for a patient whose therapy was manufactured specifically for them.
Many clinical trial technologies were designed around conventional drug supply models.
They excel at managing pooled inventory, forecasting site demand, and distributing product across large patient populations.
Cell and gene therapy operates differently.
Rather than managing inventory, sponsors are coordinating patient-specific workflows that connect clinical operations, manufacturing, and logistics.
That requires systems capable of supporting:
Without these capabilities, study teams are often forced to create manual workarounds to bridge gaps between systems.
Purpose-built RTSM platforms can play a critical role in bringing these processes together.
By embedding manufacturing and logistics workflows directly into the trial management process, RTSM becomes more than a randomization tool—it becomes a coordination platform.
For cell and gene therapy studies, this can include:
Manufacturing Slot Management
Sites can confirm patient eligibility and reserve manufacturing capacity within a controlled workflow, helping ensure production resources are allocated appropriately.
Site Readiness Verification
Readiness checks can be completed before manufacturing activities are triggered, reducing the risk of last-minute cancellations or delays.
Chain of Identity Tracking
Every handoff—from collection through manufacturing, shipment, and infusion—can be tracked and documented to maintain patient-product matching throughout the process.
Automated Workflow Controls
Alerts and notifications help teams identify issues before they impact treatment schedules, allowing corrective action to be taken earlier.
End-to-End Visibility
Sponsors gain a clearer view of where each patient is within the vein-to-vein process, improving oversight and operational decision-making.
The goal is not simply to digitize existing processes. It is to create a coordinated operational framework that reflects how cell and gene therapy trials actually run.
Cell and gene therapy represents one of the most exciting areas of innovation in clinical development. As these therapies continue to evolve, the systems supporting them must evolve as well.
Managing patient-specific manufacturing, preserving the chain of identity, coordinating logistics, and ensuring timely treatment delivery requires technology designed for these unique operational demands.
Because in cell and gene therapy, reducing supply risk isn't just about protecting inventory.
It's about protecting a patient's opportunity to receive treatment.
Endpoint Clinical's RTSM solutions are designed to support the complexity of modern clinical trials, helping sponsors coordinate manufacturing, logistics, and patient workflows with greater visibility, control, and confidence.
Why Coordination Matters More Than Inventory
.png)
Across Data, Supply, and Change
.png)
Why Modern Supply Execution Needs a Different Kind of RTSM
